Tranexamic acid-induced visual impairment in a hemodialysis patient

Clinical and Experimental Nephrology

Volumn 7, Issue 4, 2003, Pages 311-314

  Kitamura, Hiroshi ^a   Matsui, Isao ^b   Itoh, Noriko ^a   Fujii, Takashi ^a   Aizawa, Masayo ^a   Yamamoto, Ryouhei ^a   Okuno, Ayako ^a   Okazaki, Yoshihisa ^a   Fujita, Yoshimasa ^a   Kuwayama, Yasuaki ^a   Imai, Enyu ^b   Fujii, Masamitsu ^a  

^a OSAKA KOSEI NENKIN HOSPITAL   (Japan)

^b OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

CAPD; Cetraxate; Hemostat; Renal failure; Total blindness

Indexed keywords

CYANOCOBALAMIN; FLUORESCEIN; RETINOL; TRACE ELEMENT; TRANEXAMIC ACID;

ADULT; ANGIOGRAPHY; ARTICLE; BLINDNESS; CASE REPORT; DISEASE ASSOCIATION; DRUG OVERDOSE; FLUORESCENCE; HEMODIALYSIS; HOSPITALIZATION; HUMAN; KIDNEY FAILURE; KIDNEY METABOLISM; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC NERVE; PERITONEAL DIALYSIS; PIGMENT EPITHELIUM; POSTOPERATIVE COMPLICATION; RETINA; RETINOGRAPHY; ULCER; VISUAL FIELD; VISUAL IMPAIRMENT;

ANGIOGRAPHY; ANTIFIBRINOLYTIC AGENTS; GLOMERULONEPHRITIS; HUMANS; MALE; MIDDLE AGED; OVERDOSE; RENAL DIALYSIS; TRANEXAMIC ACID; VISION DISORDERS;

EID: 9144228660     PISSN: 13421751     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10157-003-0254-y     Document Type: Article

References (10)

1. Cormack F, Chakrabarti RR, Jouhar AJ, Fearnley GR. Tranexamic acid in upper gastrointestinal haemorrhage. Lancet 1973;1207-8.
2. Abiko Y, Iwamoto M. Plasminogen-plasmin system. VII. Potentiation of antifibrinolytic action of a synthetic inhibitor, tranexamic acid, by alpha 2-macroglobulin antiplasmin. Biochim Biophys Acta 1970;214:411-8.
3. Andersson L, Eriksson O, Hedlund P, Kjellman H, Lindqvist B. Special considerations with regard to the dosage of tranexamic acid in patients with chronic renal diseases. Urol Res 1978;6:83-8.
4. Eriksson O, Kjellman H, Pilbrant A, Schannong M, Pharmacokinetics of tranexamic acid after intravenous administration to normal volunteers. Eur J Clin Pharmacol 1974;7:375-80.
5. Astedt B. Clinical pharmacology of tranexamic acid. Scand J Gastroenterol Suppl 1987;137:22-5.
6. The United States Pharmacopeial Convention. Inc 1995;264-6.
7. Pilbrant A, Schannong M, Vessman J. Pharmacokinetics and bioavailability of tranexamic acid. Eur J Clin Pharmacol 1981;20:65-72.
8. Johnson NF, McKecknie N, Forrester JV. An investigation of retinal function and structure in rabbits treated long-term with tranexamic acid. Toxicol Appl Pharmacol. 1977;40:59-63.
9. Kuriyama S, Nakayama M, Tomonari H, Kawaguchi Y, Hosoya T. Tranexamic acid increases peritoneal ultrafiltration volume in patients on CAPD. Perit Dial Int 1999;19:38-44.
10. Nakayama M, Kuriyama S, Kato N, Hayakawa H, Ikeda M, Terawaki H, et al. Three CAPD cases who maintained increased ultrafiltration volume by long-term and intermittent oral administration of low dose of tranexamic acid. J Jpn Soc Dial Ther 2001;34:1333-7.